EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NUTEX Investments's Enterprise Value is Ft-3,631.20 Mil.
NUTEX Investments's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was Ft255.92 Mil. Therefore, NUTEX Investments's EV-to-FCF for today is -14.19.
The historical rank and industry rank for NUTEX Investments's EV-to-FCF or its related term are showing as below:
BUD:NUTEX'
s EV-to-FCF Range Over the Past 10 Years
Min: -56.08 Med: -3.51 Max: 19.41
Current: -14.16
During the past 13 years, the highest EV-to-FCF of NUTEX Investments was 19.41. The lowest was -56.08. And the median was -3.51.
BUD:NUTEX's EV-to-FCF is ranked better than 99.82% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.525
vs BUD:NUTEX: -14.16
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NUTEX Investments's PE Ratio (TTM) for today is calculated as:
NUTEX Investments's share price for today is Ft13.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NUTEX Investments's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was Ft3.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
NUTEX Investments EV-to-FCF Related Terms
NUTEX Investments EV-to-FCF Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NUTEX vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NUTEX Investments EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where NUTEX Investments's EV-to-FCF falls into.
NUTEX Investments's current Enterprise Value is Ft-3,631.20 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NUTEX Investments's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was Ft255.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUTEX Investments (BUD:NUTEX) has a EV-to-FCF of -14.19 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NUTEX Investments and its competitors. According to the industry distribution chart, NUTEX Investments ranks #1 out of 562 companies in the Drug Manufacturers industry, placing it in the top 0.2%.
Is NUTEX Investments' EV-to-FCF too high?
NUTEX Investments' current EV-to-FCF is -14.19. Based on the distribution chart, NUTEX Investments ranks #1 out of 562 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, NUTEX Investments has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #1 out of 562 companies for EV-to-FCF. This places NUTEX Investments in the top 0% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.53, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NUTEX Investments and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current EV-to-FCF is -14.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
Based on GuruFocus' analysis, NUTEX Investments (BUD:NUTEX) is currently considered Fairly Valued. The stock's GF Value™ is Ft13.80, compared to a current price of Ft13.40 — trading 2.9% below its estimated fair value. The current EV-to-FCF is -14.19. NUTEX Investments' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current EV-to-FCF is -14.19 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NUTEX Investments (BUD:NUTEX) Overvalued in 2026?
Based on GuruFocus' analysis, NUTEX Investments stock appears to be undervalued.
The current stock price of Ft13.40 is trading 2.9% below its estimated GF Value™ of Ft13.80.
GuruFocus considers NUTEX Investments to be Fairly Valued.
Key valuation signals for BUD:NUTEX:
EV-to-FCF: -14.19
GF Value™: Ft13.80 vs. price of Ft13.40 (2.9% below fair value)
No single metric tells the full story. See the BUD:NUTEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
50GF Score
Get the complete analysis for BUD:NUTEX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
